TOLIFE Combining Artificial Intelligence and smart sensing TOward better management and improved quality of LIFE in chronic obstructive pulmonary disease
- Coordinator
- Universita Di Pisa, Italy
- Runs
- 1 September 2022 to 28 February 2027
- Status
- Running
- EU funding
- €6.4m
- Total cost
- €6.4m
- Partners
- 15 organisations in 6 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101057103
What the project is doing
In the project's own words, from its summary on CORDIS.
Chronic obstructive pulmonary disease (COPD) is a highly prevalent chronic condition. While COPD is a lung disease, it is mainly the exacerbations and extrapulmonary comorbidities which affect the quality of life, health care costs, and prognosis. The optimal COPD treatment needs to focus on both the characteristics and consequences of the lung disease itself and the diagnosis and treatment of comorbidities. While the severity of lung function impairment is routinely assessed, the exacerbations, the associated comorbidities and limitations in daily life are still significantly underestimated.
A personalized approach to COPD management is needed to specifically address the disease, prevent exacerbations, and mitigate its comorbidities to obtain a positive impact on patient health and quality of life. TOLIFE will clinically validate an artificial intelligence (AI) solution to process daily life patient data captured by unobtrusive sensors to enable optimised personalised treatment, assessment of health outcomes and improved quality of life in COPD patients.
The TOLIFE approach to COPD management, targeted to predict and mitigate exacerbations and continuously assess the health outcomes, has the potential to reduce mortality, improve health related quality of life and reduce the healthcare costs. TOLIFE will develop and clinically validate an AI-based platform for the early prediction of exacerbations and assessment of the health outcomes. Prediction of exacerbations and assessment of health outcomes will be exploited by clinicians through a patient management tool to perform early and personalized treatment.
TOLIFE platform will inform through a disease information tool the patient and caregivers about the patient's health status, the specific treatment plan and lifestyle indications. Two clinical studies will be implemented, one to collect data for AI-tools development and the other to validate the effectiveness of TOLIFE to reduce the risk of exacerbations.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universita Di Pisa | Pisa | Italy | Coordinator |
| Bewarrant | Bruxelles | Belgium | Participant |
| Timelex | Bruxelles / Brussel | Belgium | Participant |
| Velocity Clinical Research Grosshansdorf GmbH | Grosshansdorf | Germany | Participant |
| Thorax Research Foundation | Athens | Greece | Participant |
| Avvale Espana SL | Madrid | Spain | Participant |
| Consorcio Mar Parc De Salut De Barcelona | Barcelona | Spain | Participant |
| Fundacion Privada Instituto De Salud Global Barcelona | Barcelona | Spain | Participant |
| Universidad Politecnica De Madrid | Madrid | Spain | Participant |
| Adatec Sensing & Automation SRL | Lucca | Italy | Participant |
| Avvale S.p.a. | Milano | Italy | Third party |
| Consiglio Nazionale Delle Ricerche | Roma | Italy | Participant |
| Istituto Superiore Di Sanita | Roma | Italy | Participant |
| Tinexta Innovation Hub S.p.a. | Correggio Re | Italy | Third party |
| European Federation of Asthma &allergy Associations Ideell Forening | Brussel | Sweden | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI